• A leading provider of audience-driven business intelligence and marketing solutions
• Flagship SWARM solution applies advanced data science, behavioral science, artificial intelligence, and market research techniques to deliver powerful audience-driven business intelligence that convert opportunities into business success
• Creating shareholder and corporate value through strategic acquisition of profitable solutions providers backed by strong management teams
• Global business intelligence (BI) market forecast to reach $34.3 billion by 2022 at the compound annual growth rate of 11.03%

CloudCommerce Inc. (OTCQB: CLWD) is a leading provider of audience-driven business intelligence and marketing solutions. Together with its wholly owned subsidiaries, CloudCommerce delivers invaluable end-to-end business intelligence and marketing solutions through a range of services and capabilities.

Flagship Solution

SWARM is an end-to-end solution that applies advanced data science, behavioral science, artificial intelligence and market research techniques to deliver powerful audience-driven business intelligence that converts opportunities into business success.

Through marketing, brand perception, customer-relationship management, human-resources management and operational logistics applications, CloudCommerce’s SWARM solution helps businesses determine who to talk to, what to say and how to motivate targeted audiences to take meaningful action.

The Market

Marketers have largely taken a blanket approach to communication. The same messages are often sent across an entire customer audience with little regard for how different groups of people communicate, build communities and develop their purchasing habits. When marketers do segment audiences, they use objective selection criteria such as income, geography, education or purchase history to deduce attitudes or intentions.

However, research shows that motivations and feelings are much more accurate at predicting behavior. The challenge for businesses is that these factors are also the hardest to gather from audience data. CloudCommerce provides that audience-intelligent data through SWARM, its proprietary behavioral-science approach to audience creation and communication. Through SWARM, CloudCommerce helps marketers identify consumer motivations and triggers in order to effectively predict and influence actions. When companies influence action, they can change opinions, gather support, motivate purchases and inspire change.

In a fast-developing global business intelligence market estimated to grow from $16.3 billion in 2016 to $34.3 billion by 2022, CloudCommerce stands apart as an innovator and true partner, able to deliver data-driven intelligence and solutions that enable its customers to strengthen their brands, deliver their messages and reach their goals.

SWARM Products

THE SWARM—Intelligent Audience Building
The core of the CloudCommerce solution – and what separates CloudCommerce from other audience data companies – is the company’s unique approach to audience building. The concept of “personas” has been around for decades, but CloudCommerce takes that concept to the next level. The SWARM was developed to identify not only who to talk to but also what to say in order to motivate target audiences to take meaningful action. Using CloudCommerce’s proprietary clustering and behavioral analysis techniques, businesses can identify target audiences and deliver messages that are more focused and efficient. CloudCommerce not only helps its client partners find the right people to talk to but also identifies the most powerful message to send.

BUZZ—Behavior-Based Market Research
Market research is evolving. Research techniques developed and used today are more sophisticated and backed by strong data science. Despite these changes, many traditional research firms have failed to innovate: small sample sizes, survey design bias, improper weighting and gut-intuition sampling are just some of the issues that plague the market-research industry. Through BUZZ, CloudCommerce has automated the market research process to provide a level of statistical depth beyond what traditional firms can offer. BUZZ offers businesses the ability to put their finger on the pulse of the marketplace in the moment. Using a wide range of internal and external data sources such as customer data, social media activity, and micro and macro trends, BUZZ deduces attitudes, emotions and opinions.

HIVE—Redefined Geographic Targeting
Conventional geographic audience targeting is outdated. Arbitrary units of location such as counties, cities, DMAs and regions were created centuries ago based on land-rights ownership. Their use in understanding people’s behavior, purchase habits and underlying values is minimal. CloudCommerce has found a much more powerful, efficient and effective way of targeting by clustering people into granular geographic tribes called HIVES. HIVES are defined by attributes such as common language (e.g., colloquialisms), shared experience and narratives (e.g., climate, history), and concentrated demography and biology (e.g., ethnicity, age). Based on the needs of its clients, CloudCommerce can completely redraw the geographic lines based on various Hive selection criteria. Using this exclusive HIVE approach, CloudCommerce clients experience more efficient and effective marketing, make more intelligent business decisions and enjoy more growth.

HONEY—Advanced Reporting and Visualization
Advanced-audience, data-analysis technologies are useless if they don’t produce simple, powerful and actionable business intelligence. HONEY comes with user-friendly reporting and visualization tools to organize and explain all of the advance-data science into a simple-to-understand format for decision makers. HONEY combines the intelligence of client CRM data with third-party consumer data and targeted market research to create a powerful foundation for any audience-intelligence solution.

Subsidiaries

Data Propria
Data Propria delivers the highest Return on Investment (“ROI”) for their customers’ digital marketing campaigns, by utilizing sophisticated data science to identify the correct universes to target relevant audiences. Their ability to understand and translate data drives every decision they make. By listening to and analyzing their customers’ data they are able to make informed decisions that positively impact their customers’ business. Data Propria leverages industry-best tools to aggregate and visualize data across multiple sources, and then their data and behavioral scientists segment and model that data to be deployed in targeted marketing campaigns. They have data analytics expertise in retail, wholesale, distribution, logistics, manufacturing, political, and several other industries.

Parscale Digital
Parscale Digital helps their customers get their message out, educate their market and tell their story. They do so creatively and effectively by deploying powerful call-to-action digital campaigns with national reach and boosting exposure and validation with coordinated advertising in print media. Parscale Digital’s fully-developed marketing plans are founded on sound research methodologies, brand audits and exploration of the competitive landscape. Whether their customer is a challenger brand, a political candidate, or a well-known household name, Parscale Digital’s strategists are skilled at leveraging data and creating campaigns that move people to make decisions.

Giles Design Bureau
Giles Design Bureau approaches branding from a “big picture” perspective, establishing a strong identity and then building on that to develop a comprehensive branding program that tells the customer’s story, and articulates what sets the customer apart from their competitors and establishes the customer in their market.

WebTegrity
WebTegrity develops commerce-focused, user-friendly digital websites and apps that elevate their customer’s marketing position and draw consumers to their products and services. Their platform-agnostic approach allows WebTegrity to architect and build solutions that are the best fit for each customer. Once the digital properties are built, their experts will help manage and protect the website or app and provide the expertise needed to scale the infrastructure needed as the customer’s business grows.

Leadership

Andrew Van Noy, CEO & Chairman of CloudCommerce Board of Directors
Andrew Van Noy has been a director of CloudCommerce since November 2012, president of the company since April 2012, and the CEO of the company since August 2012. He also served as executive vice president of CloudCommerce from November 2011 to April 2012 and vice president of Sales and Marketing of the company from May 2011 to November 2011. From January 2009 to April 2011, Van Noy served as the vice president of Sales and Marketing for PageTransformer, which provided web and software development for iPad, iPhone and Android devices. Van Noy came to CloudCommerce with experience in digital marketing, private equity and investment banking. During his years at the company, Van Noy led the efforts to rebrand and restructure the business and presided over the acquisition of a number of companies. Van Noy graduated from BYU with a Bachelor of Science degree.

Gregory Boden, CFO and Board of Directors
Gregory Boden became a director at CloudCommerce in November 2011 and in February 2013 was named corporate secretary. In April 2012, Boden was also appointed CFO. In addition, Boden is the managing partner of a private equity company. Prior to joining the CloudCommerce team, Boden managed the franchise accounting and cash application departments of Select Staffing, a nationwide staffing company and was an accountant at KPMG LLP. Boden earned his master of accountancy degree from the University of Denver.

Brad Parscale, Board of Directors
Brad Parscale creates web-marketing strategies and oversees all technical and functional aspects of these strategies. Originally from Kansas, Parscale spent five years in California before moving to San Antonio in 2004 to establish Parscale Media, a successful web-marketing firm. His 2011 partnership with Jill Giles formed Giles-Parscale Inc. In 2016, Parscale was named digital director for the Donald J. Trump presidential campaign.

Zachary Bartlett, VP of Corporate Development and Board of Directors
Zachary Bartlett has been a director of the company since July 2012 and was appointed vice president of Corporate Development in January 2018. Bartlett has also served as vice president of Communications and an independent contractor assisting with project management matters. Prior to joining CloudCommerce, Bartlett was the creative director at Crowbar Studios Inc., a graphic design and web development firm he founded in 2008. From 2004 to 2008, he held the position of art and brand consultant at Demon International, a snowboard accessories company. Bartlett earned his bachelor of fine arts degree in graphic design from Brigham Young University.

For more information, visit the company’s website at www.CloudCommerce.com

NOTE TO INVESTORS: The latest news and updates relating to CLWD are available in the company’s newsroom at http://ibn.fm/CLWD

• The direct-selling industry is seeing rapid global growth with the ongoing shift toward a gig economy
• Sharing Services aims to empower independent business leaders to take charge of their own lives while creating record-breaking sales
• The company’s products utilizing dopamine, oxytocin, serotonin and endorphins create elevated happiness levels and are well-received by the market

The direct-selling industry has seen rapid growth globally. Estimated retail sales in 2018 marked a 1.2 percent increase over the previous year, bringing in $192.9 billion (http://ibn.fm/V16x9). More and more people are relying on gig jobs that allow them to avoid long commutes to the office, restricted work hours and bosses. Sharing Services Global Corporation (OTCQB: SHRG) is one of many companies making these conveniences possible in this emerging gig economy, but SHRG stands apart from the others due to its commitment to thoroughly empowering the home-based entrepreneur.

The company calls its independent distributors ‘Elepreneurs’, and it is reshaping the industry by providing necessary tools that can lead individuals to success. From its headquarters in Plano, Texas, the company provides Elepreneurs with quality training, products and services. All of the company’s sales are through organic growth, which is attributed to the Elepreneurs, who are effectively following the company’s Blue Ocean Strategy. Since 2017, the company has added thousands of independent distributors and continues to see growth.

Elepreneurs are focused on elevating their own lives and the lives of customers through products and services. By empowering entrepreneurs to take the reins of their own lives, Sharing Services has created a simpler, more inventive approach to sales and marketing that harnesses the power of relationship marketing. Today’s consumers are reached through cost-effective and personal approaches that other organizations have lacked the ability to accommodate. SHRG Elepreneurs are taught how to connect with others, utilize social media tools and grow organic friendships through excellent customer service. These skills in utilizing customers’ online presence to cultivate personal connections are setting Elepreneurs LLC apart from other direct-selling companies.

SHRG also has a competitive advantage as it taps into the health and wellness market. Wellness products make up an estimated 33.8 percent of America’s direct-selling industry. Synergizing the customer service talents of Elepreneurs with SHRG’s happiness-stimulating products, the company has been able to increase its products’ market penetration.

These products, which are designed to elevate the happiness and well-being of customers, have been created through SHRG’s wholly owned subsidiary, Elevacity LLC. The brand is made up of core products in the nutritional category, including supplements that incorporate the company’s formulation of dopamine, oxytocin, serotonin and endorphins, or D.O.S.E. These four hormones have been shown to promote well-being and happiness.

Backed by scientific data and well-known happiness researcher Shawn Achor (http://ibn.fm/yeP5F), the D.O.S.E. products have been well received and are a large reason for SHRG’s record-breaking sales since the products debuted in December 2017. Whether customers start their day with a D.O.S.E. of happiness mixed with their coffee or in a supplement, they know they are using a product that’s made with the highest standards.

SHRG seems to have found its niche as it focuses on creating products and services that impact the happiness of customers, entrepreneurs and investors alike.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• The company recently completed clinical trials for its acute pain formulation, CTL-X, which is the most advanced product in the Veritas pipeline
• Veritas Pharma works in two directions to put together effective cannabis-based treatments for various medical conditions
• With the help of R&D partner Cannevert Therapeutics, Veritas is developing solutions for various additional issues like chronic pain and sleep disorders

Pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is on a mission to develop the most effective proprietary cannabis strains and products for the treatment of various medical conditions. The company focuses on providing both physicians and patients with conclusive evidence for the recommendation of medical marijuana.

In the spring of 2019, Veritas announced the results of its product clinical trials in support of the company’s commitment to developing the most effective products (http://ibn.fm/dgy4C). The cannabis treatment clinical trial (randomized, double-blinded, cross-over) tested the effectiveness of the company’s vaporized CTL-X acute pain product. Studies were carried out following GMP standards over the course of three months. The results provide real scientific evidence of the use of cannabis for medical purposes and, more specifically, for the treatment of acute pain.

“We believe that for millions of people suffering from acute pain vaporized cannabis can potentially reduce the need for other medications, including opioids. From results of this study, clinicians will have a better understanding for specific dosage and delivery of cannabis for acute pain,” Veritas Medical Director Dr. Scott Alexander stated in a news release.

Veritas’ innovative research and development approach aims to solve the critical need for scientific research to support claims about the effectiveness of cannabis-based treatments. Through its research and development subsidiary, Cannevert Therapeutics Ltd., Veritas is developing innovative products for the treatment of various medical conditions like chronic and acute pain, sleep disorders and palliative care.

Cannevert has screened numerous cannabis strains to pinpoint their potential in treating chronic pain and reducing the need for opioid administration. Acute pain treatment CTL-X is the most advanced product in the Veritas pipeline and therefore the focus of its clinical trial efforts.

Veritas is also concerned with sleep disorders and the growing prominence of the conditions. Studies show that Americans are now getting one to two hours less sleep than previous generations (http://ibn.fm/yIp3V). In 1942, only 11 percent of Americans slept six hours or less per night. By 2013, the number had increased to 40 percent of the adult population, the American Association of Retired Persons (AARP) reported.

Through its research, Veritas is attempting to identify cannabis as a reliable solution to this growing problem. There is some anecdotal evidence, and Cannevert is working to develop biological assays to identify the most effective strain for the treatment of insomnia, parasomnia, chronic fatigue syndrome and others.

Based at the University of British Columbia, Cannevert has brought together a team of pharmacologists, chemists and anesthetists who have substantial prior experience in drug development. Through the partnership, Veritas gains the technical ability to achieve its effective treatment development vision.

For more information, visit the company’s website at www.VeritasPharmaInc.com

• Trxade Group’s supplier-to-pharmacy network, delivery services and data analytics platform are empowering independent pharmacies struggling to stay in business amid competitive challenges
• The company reported record revenues of $1.9 million for the most recent quarter, as well as other improvements to its top and bottom lines
• The plight of independent pharmacies has caught the attention of state officials in Illinois, who recently enacted Illinois’ first oversight system for the middlemen who manage pharmacy costs and reimbursement rates

Independent pharmacies in Illinois are celebrating recent state legislative action that strengthens small businesses involved in dispensing quality of life-enhancing medications to their customers, an empowerment trend that pharmaceutical services company Trxade Group Inc. (OTCQB: TRXD) has taken to heart as it builds its own growing network of independent pharmacies across the country.

Many of those mom-and-pop pharmacies have found it necessary to close up shop due to a variety of economic conditions, creating what have come to be known as ‘pharmacy deserts’, where residents remain without close-to-home options for fulfilling their prescription needs, especially if they are looking for a familiar business that knows its neighbors and goes the extra mile to assist them (http://ibn.fm/EVkGM).

Low insurer reimbursement rates have become a common complaint among community-oriented small business pharmacies nationwide. Several pharmacists have blamed the pharmacy benefit manager (PBM) middlemen who negotiate costs between pharmacies and insurers, such as Medicare, Medicaid and commercial health plans, arguing that the PBMs improperly drive up the costs of doing business and thereby force small pharmaceuticals out of business (http://ibn.fm/BGoRl).

Trxade’s network offers a platform for buying medications at competitive prices, as well as services for storing pharmaceuticals and delivering them directly to consumers, with an aim of helping sustain independent pharmacists amid their industry difficulties. Illinois’ legislature provided additional relief that was hailed by the Illinois Pharmacists Association in August by passing a bill that creates its first oversight system for PBMs, as reported by The State Journal-Register (http://ibn.fm/XtEA3). The state has also budgeted millions of dollars for pharmacy assistance out of concern for the small, independent shops, the report states.

Michelle Dyer, who operates three Michelle’s Pharmacy stores in the state, applauded the new law as “a great step to reign in the abusive powers that PBMs use against independent pharmacies,” adding that PBMs are “creating unprofitable environments that make it difficult to sustain business for independent pharmacies, and the result is that we’re seeing these businesses closing all the time in central Illinois,” according to the report.

Trxade’s own private enterprise approach to keeping the lifeblood flowing in independent pharmacies’ veins has seen its financial top and bottom lines grow. Its most recent quarterly report displays record revenue growth, as well as an increase in gross profits and a growing number of subscribers to the pharmacy network.

The company reported that revenues for the three months ended June 30 were over $1.9 million, marking an increase of 129 percent year-over-year. It also marked a 27 percent sequential increase over the first quarter ended March 31 (http://ibn.fm/hOCza).

“We made excellent progress executing against our key strategic priorities in our Delivmeds.com program, our B2C commercial efforts and our proprietary B2B trading platform www.Trxade.com,” Chairman and CEO Suren Ajjarapu stated in a news release. “Accordingly, I am optimistic that our new product lines will generate profitability as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing medication.”

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Texas-based Neutra Corp. produces nutraceutical vapor products and is expanding into hemp cultivation and purified hemp extract products
• The wellness product industry measures in the trillions of dollars, growing faster than the global economy, and the hemp cultivation industry is expected to top $26 billion by 2025
• The LOI for Vivis would grant Neutra Corp. an established brand of products built on crystalline CBD and full-spectrum CBD extract, while the J3 Holdings LOI would deliver land, a warehouse and a license to cultivate and refine hemp

The growing focus on health and wellness products and philosophies during recent decades has created a bustling marketplace in which businesses and consumers work collaboratively on wallet-friendly ways to love life in the living of it. Neutra Corp. (OTCQB: NTRR) is an interested player in the arena, advancing its interests in monetizing early stage research and development efforts to build a better human body and global environment by growing vertically within the nutraceuticals, food and drug, and environmental purification sectors.

Neutra Corp. has recently pursued the acquisition of companies that hold licenses to cultivate and process hemp, and to sell established high quality, high potency hemp-extracted products, through letters of intent that would bring the subsidiaries’ strengths into the fold.

The Global Wellness Institute reported last fall that the wellness industry grew by 6.4 percent each year from 2015 to 2017, topping $4.2 trillion as a market growing nearly twice as fast as the global economy (http://ibn.fm/FyvcI) as a result of concerns over the rising costs of health care and growing reporting of select chronic ailments among younger-than-traditional populations. The global hemp industry is expected to experience a CAGR of 34 percent from now to 2025, according to Research and Markets analysts, growing from $4.6 billion to $26.6 billion (http://ibn.fm/yEW8k).

Neutra Corp.’s efforts to develop its portfolio demonstrate its recognition of the market factors in play, as well as its conscientiousness in making a quality of life difference for people. Medical-grade hemp extracts have gained a reputation for helping people to manage pain and anxiety, whether from chronic diseases, athletic injuries or everyday aches and pains.

The company has entered two LOIs for emerging hemp retail brand Vivis and hemp cultivator J3 Holdings. The Vivis acquisition “will give Neutra Corp. an even stronger market presence with an established brand already recognized for superiority,” Neutra Corp. President and CEO Sydney Jim stated in a news release (http://ibn.fm/vtDdG).

Vivis has a product line that uses a 99 percent or higher grade of hemp-extracted crystalline CBD, and the firm is preparing to launch a second brand with an 80 percent or higher grade of full-spectrum CBD extract. Vivis’ extracts are certified by a third-party lab to ensure their quality.

J3 Holdings has land, a warehouse and a license to cultivate and refine hemp that are expected to prove valuable additions to Neutra Corp.’s stable.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• Renewed health in the oil and gas sectors show an ongoing need for products such as Petroteq Energy’s closed-loop, clean surface extraction CORT operation
• Petroteq is developing what it believes to be the next big thing in the industry after fracking generated a domestic oil production boom in the United States
• While performing maintenance and upgrades at its Utah production site, Petroteq continues to demonstrate its technology’s potential through licensing and lab testing

A new year of continuing recovery in the oil and gas markets has industry watchers enthused about the outlook for U.S. productivity for domestic and international consumers during the coming decades, with production currently hovering at a level of 19-20 million barrels per day. Demand for U.S. oil is “buoyantly very high,” with more than 2.5 million barrels per day of crude oil exported in April, according to Forbes (http://ibn.fm/4BG8v), at a rate that was 35 percent higher than the previous April. Oil product exports, on the other hand, were double that amount.

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is building momentum as an innovator of CORT (Clean Oil Recovery Technology) and is making surface tar sands oil extraction cleaner and simpler than ever. Through a closed-loop recovery process conducted at ground level, Petroteq is removing bituminous oils from the tar sands that are plentiful in Utah’s rural eastern desert and leaving behind sands that are clean enough to grow produce.

CEO David Sealock showcased the operations processes of the company’s two-year labor of love at Utah’s Asphalt Ridge in a video tour of Petroteq’s facilities published in June (http://ibn.fm/qnZwt) in celebration of phase I production.

The company halted operations in order to perform planned equipment re-engineering. The coarseness of the Utah desert sands interfered with initial efforts to arrive at an earlier deadline, but the maintenance alterations to the equipment are expected to decrease the costs of further maintenance in the future and improve the facility’s efficiency in reaching its production goals.

While the facility upgrade advances toward recommencement of production, Petroteq has been pressing the advantages of its technology with other companies in the United States and abroad, approving its first non-exclusive licensing agreement with eastern Texas energy services company Valkor LLC in July and completing demonstrative lab projects for Asian and Australian interests that show the ability of Petroteq’s technology in recovering oil from tar sands and shale (http://ibn.fm/UDwtL).

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018
• Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities
• The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent
• Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016
• Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery, reducing the need for pain medications that can lead to addiction
• The company’s proprietary wearable device can be used for a wide range of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue

Finding answers to the nation’s opioid epidemic is a complex problem being fought on several fronts. In a news release, Alan Collier, chief executive officer of Endonovo Therapeutics Inc. (OTCQB: ENDV), stated that the company’s SofPulse post-operative opioid alternative medical device delivers clinically-proven post-surgical pain relief to patients.

“With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis,” Collier noted (http://ibn.fm/ksEeK).

Federal statistics show that opioids kill more people per year than car crashes on America’s roadways. An estimated 68,000 Americans died from a drug overdose stemming from opioid abuse in the United States in 2018, although that number could rise once final numbers are compiled, according to Centers for Disease Control and Prevention (CDC) reports (http://ibn.fm/Kd4TZ).

The CDC reported that, in 2016, 11.5 million people misused opioids (http://ibn.fm/NY2Dh), while the Department of Justice reports that four out of five heroin users first misused prescription opioids (http://ibn.fm/meham).

Drug overdose deaths involving any opioid rose from 18,515 deaths in 2007 to 47,600 in 2017, with 68 percent of those deaths occurring among men, per CDC data. In addition, the National Safety Council reports that impaired driving caused by drugs, including opioids, contributed to some of the 40,000 fatal crashes that occurred in each of the past three years (http://ibn.fm/gqf93).

Endonovo’s SofPulse provides targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue. Endonovo’s SofPulse is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving patients’ natural recovery experiences (http://ibn.fm/BxHsd).

Endonovo’s Electroceutical Therapy(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical Therapy represents “a fascinating new frontier.” Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist.

“Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” Novak stated in a news release (http://ibn.fm/RPZRt). “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• The hemp-derived CBD market is projected to reach $22 billion by 2022
• The company recently entered into a tolling agreement to process five million kilograms of hemp biomass
• HTC has entered into an agreement with Canaccord Genuity Corp. for a C$15 million bought deal private placement

With the passage of the Agriculture Improvement Act of 2018 (commonly known as the 2018 farm bill), hemp production and distribution in the United States became permissible under federal law. Freed from its legal shackles, the industry is experiencing rapid growth. As production and distribution of hemp increases, the business of extracting CBD from hemp biomass, as opposed to extraction from marijuana, is looking more feasible, so much so that industry analyst Brightfield Group projects that the hemp-derived CBD (cannabidiol) market will grow to $22 billion by 2022 (http://ibn.fm/xD28h). This market expansion is already increasing demand for extraction technology such as the Delta Purification System provided by HTC Extraction Systems (TSX.V: HTC). The company has inked one agreement and is in negotiations with other biomass providers in Canada and the United States.

HTC’s proprietary biomass processing occurs in three phases: pre-oil preparation, oil extraction and oil refinement. During the pre-oil extraction stage, the hemp is pulverized and dried. The resulting biomass is then immersed in ethanol, and the resulting mixture – containing cannabinoids, oils, ethanol and plant liquids – is separated from the plant fibers. During the last phase, the oil is collected, with 90 percent of the ethanol being removed and recycled, resulting in an approximate 50 percent CBD crude oil. The crude is then subjected to further distillation to achieve full spectrum oil (FSO) and/or pure CBD isolate.

HTC recently announced its entry into a hemp biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://ibn.fm/hjw4g). The agreement covers 4,200-5,000 acres of hemp in Saskatchewan, utilizing five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process an estimated five million kilograms of hemp biomass to extract CBD full-spectrum oil (FSO). The company will be paid a “toll fee,” or a percentage of the extracted CBD FSO distillate, for its processing, extraction, purification and distillation services. Toll fees are payments made to companies that provide specialized manufacturing or processing services.

Additionally, HTC is in negotiations with a large hemp biomass producer that has some 60,000 acres of hemp under cultivation. The company intends to enter into a tolling contract with this producer for production crop years 2019, 2020, 2021 and beyond. Hemp biomass tolling contracts with producers are also being negotiated in the United States for the 2020 hemp-crop growing year, under which HTC will provide local-to-grower, drying-to-biomass storage capability and transportation of dried biomass to an HTC extraction facility.

HTC boosted its capital in 2019 by entering into a letter agreement, with Canaccord Genuity Corp. acting as sole book runner and lead underwriter on behalf of a syndicate of underwriters that have agreed to purchase, subject to completion of due diligence, on a bought-deal, private-placement basis, 15 million units of the company’s common shares, at a price of C$1 per unit for aggregate gross proceeds of C$15 million (http://ibn.fm/ZTiVq).

With such endorsements, HTC seems set to capitalize on the mushrooming hemp biomass extraction business.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• A rapidly aging population and technological advances are contributing to the fast growth of the global pain management device market
• The market is currently dominated by neurostimulation devices, which accounted for half the revenue reported in 2018 – a trend that’s likely to continue over the next few years
• Endonovo Therapeutics is already establishing a leading position in the niche; the company’s SofPulse(R) pain management device has been rolled out in a national network of hospitals, clinics and pain management centers for thorough evaluation

The global pain management device market is anticipated to grow rapidly through 2026, expanding at a CAGR of 13.8 percent to reach $14.55 billion, according to Grand View Research’s recent ‘Pain Management Devices Market Size, Share & Trends Analysis Report’ (http://ibn.fm/0WD5t).

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical Therapeutic devices that target patient pain and inflammation while supporting wound recovery, has already developed its proprietary bioelectronics pain management device called SofPulse. The FDA-cleared device is proven to decrease pain by reducing swelling (edema) to address multiple medical conditions and help the recovery of patients after surgery.

Several factors will contribute to the sustainable growth of the global pain management device market, such as the rapidly aging population worldwide and the fact that a growing part of the population has started showing a preference for pain management devices over oral drugs administered in the aftermath of a surgical intervention.

Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50 percent of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period.

Recently, Endonovo announced the rollout of SofPulse in hospital and medical centers across the U.S. The company plans to be in the evaluation stage with 600 hospitals within the next 18 months. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Endonovo CEO Alan Collier said in a news release.

The public is demanding pain management options that offer an alternative to opioids. According to a recent Washington Post article (http://ibn.fm/hWkZ6), “Forty-eight states plus around 2,000 local and tribal governments have sued companies in the drug industry, arguing those that make, distribute and sell the drugs are partly responsible for a crisis that has killed more than 400,000 people across the country since 2000, according to the U.S. Centers for Disease Control and Prevention.” However, Collier emphasizes that there are currently very few products that can meet the demand. SofPulse is thus positioned to offer a safe and reliable pain management alternative.

The device works by delivering targeted pulse electromagnetic therapy. Targeted microcurrents deliver gentle pulses to affected tissues, reducing post-surgical pain and decreasing the need for the administration of pharmaceuticals by 2.2 times.

Endonovo’s proprietary technology is an effective treatment for inflammatory conditions, cardiovascular diseases and central nervous system disorders. The device has Federal Drug Administration (FDA) clearance for the treatment of post-surgical pain and edema and has also received CE marking in Europe for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at  http://ibn.fm/ENDV

• The Green Organic Dutchman is a cannabis-focused research and development company
• The company recently completed its inaugural shipment to the Ontario Cannabis Store, marking its entry into the recreational cannabis market
• TGOD continues to explore strategic worldwide opportunities

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is a leading producer of premium, certified-organic cannabis. Licensed to cultivate medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), the company produces organic medical cannabis in small batches using all-natural, organic, craft-growing principles. TGOD recently entered into the recreational cannabis market, where consumers are seeking a premium organic product.

With head offices in Mississauga, Ontario, TGOD has a planned capacity of 219,000 kilograms and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. TGOD cultivates its cannabis in a proprietary living soil, without irradiation and in accordance with all-natural principles. The company’s growing process has earned organic certification from Pro-Cert and ECOCERT, both of which are leading organic certification organizations (http://ibn.fm/ZS9Ui).

TGOD’s hybrid facilities offer key advantages over outdoor, indoor and greenhouse facilities. Those advantages include advanced humidity, temperature and overall environmental controls relative to traditional greenhouses. Advantages also include highly automated and positive-pressure rooms that lessen the chance of contaminants.

TGOD recently completed its inaugural shipment to the Ontario Cannabis Store, officially marking the company’s entrance into Canada’s recreational market. In today’s increasingly competitive cannabis market, consumers are developing distinct preferences, especially for organic products. A recent study indicated that over 50 percent of consumers are looking for their cannabis to be organic (http://ibn.fm/MahYL), and Ontario consumers are now able to experience TGOD’s acclaimed Unite Organic dried flower. The company’s high-THC (tetrahydrocannabinol) signature strain is available on www.OCS.ca and at select retail locations across the province of Ontario (http://ibn.fm/IoeTF).

“We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers,” TGOD CEO Brian Athaide stated in a news release. “Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients. Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply.”

In addition, TGOD continues to provide its products to its medicinal patients throughout Canada. TGOD products were initially available only to a small group of medical patients known as the Grower’s Circle. Subsequently, the company also signed supply agreements with the provinces of Alberta and British Columbia.

Growing to scale, TGOD has unique partnerships in place. The company’s partners include international power-management company Eaton Corp., which provides research and optimization that will enable TGOD to have some of the lowest electricity input costs in the business. This is an essential step in the company’s plan to become one of the lowest-cost producers in Canada. Eaton designed TGOD’s power-management system, and TGOD purchases its power from HCE Energy, owned by the city of Hamilton, Ontario. TGOD utilizes Hydro-Quebec in Valleyfield. The company has another key partnership with construction-management firm Ledcor. The focus of this partnership is on ensuring logistical and infrastructure controls. Ledcor specializes in project and construction management, preconstruction services, design-build and general contracting. TGOD’s alliance partners, which also include Neptune, Mediakos and Symrise AG, are industry leaders, enabling the company to achieve its energy and production goals.

TGOD continues to focus on becoming the largest organic cannabis company in the world. By taking advantage of innovative technology and low-cost power solutions, the company offers investors the potential for substantial ROI. With its proven management team, TGOD is positioned for continued expansion and sales across North America, Latin America and Europe, especially considering its recent entry into the recreational cannabis market

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF